CTIS2022-501139-17-01
Recruiting
Phase 1
A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer - PEAPOD-FOS04/2022
Fundación Oncosur0 sites42 target enrollmentAugust 26, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Fundación Oncosur
- Enrollment
- 42
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male participants who are at least 18 years of age on the day of signing informed consent., Have adequate organ function as defined in the following table (Table 1\). Specimens must be collected within 10 days prior to the start of study intervention., Criteria for known Hepatitis B and C positive subjects a.Hepatitis B and C screening tests are not required unless: •Known history of HBV or HCV infection •As mandated by local health authority b.Hepatitis B positive subjects •Participants who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization. •Participants should remain on anti\-viral therapy throughout study intervention and follow local guidelines for HBV anti\-viral therapy post completion of study intervention. c.Participants with history of HCV infection are eligible if HCV viral load is undetectable at screening. •Participants must have completed curative anti\-viral therapy at least 4 weeks prior to randomization., Histologically confirmed diagnosis of adenocarcinoma and/or neuroendocrine carcinoma of the prostate will be enrolled in this study., Presence of metastatic disease documented on imaging studies (bone scan, computed tomography (CT) and/or magnetic resonance imaging (MRI) scans, At least one of the following Aggressive Variant Prostate Cancer (AVPC) Criteria a.Histologically proven small cell (neuroendocrine) prostate cancer b.Exclusive visceral metastases c.Predominantly lytic bone metastases d.Bulky lymph nodes (\= 5 cm in longest dimension) or high\-grade pelvic/prostatic masses e.Low PSA (\=10 ng/ml) at initial presentation in the presence of extensive disease (\=20 metastases) f.Elevated serum LDH (\=2 x ULN) or CEA (\=2 x ULN) or 7\) g.Short time to castration\-resistance (\=6 months)., A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least after the last dose of study treatment and refrain from donating sperm during this period, The participant (or legally acceptable representative if applicable) provides written informed consent for the trial., Have measurable disease based on RECIST 1\.1\. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions., Have provided archival tumor tissue sample obtained in the previous year since or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated. Formalin\-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue., Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\. Evaluation of ECOG is to be performed within 7 days prior to the first dose of study intervention.
Exclusion Criteria
- •Has received prior therapy with an anti\-PD\-1, anti\-PD\-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co\-inhibitory T\-cell receptor (e.g., CTLA\-4, OX 40, CD137\)., Has severe hypersensitivity (\=Grade 3\) to pembrolizumab, carboplatin or cabazitaxel and/or any of its excipients., Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed., Has a history of (non\-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease., Has an active infection requiring systemic therapy, Has congestive Heart failure NYHA \=2\., Has hypoacusis grade \=2\., Has a known history of Human Immunodeficiency Virus (HIV) infection, Concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV DNA) and Hepatitis C virus (defined as anti\-HCV Ab positive and detectable HCV RNA) infection., Has a history or current evidence of any condition, therapy, or laboratory abnormality or other circumstance that might confound the results of the study, interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator., Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial., Has received prior systemic anti\-cancer therapy including investigational agents within 4 weeks prior to informed consent signature., Has had an allogenic tissue/solid organ transplant., Has received previous treatment with cabazitaxel or carboplatin., Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation\-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1\-week washout is permitted for palliative radiation (\=2 weeks of radiotherapy) to non\-CNS disease, Has received a live vaccine or live\-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed., Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention., Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug., Known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded., Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Phase II trial of Pembrolizumab in combination with Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)Advanced, Recurrent or Metastatic Endometrial CancerMedDRA version: 12.0 Level: HLGT Classification code 10007129 Term: Cancer-related morbidities System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-002824-26-ESVall d' Hebron Institute of Oncology (VHIO)51
Recruiting
Not Applicable
Phase II trial of pembrolizumab in combination with paclitaxel in the hormone receptor-positive metastatic breast cancer with high tumor mutational burden selected by whole exome sequencing: Korean Cancer Study Group trialKCT0007042Yonsei University Health System, Severance Hospital52
Active, not recruiting
Phase 1
A phase II clinical trial of Pembrolizumab in combination with Carboplatin-Paclitaxel in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancer: MITO28/MANGO OV4 studyadvanced (stage III B-C-IV) ovarian, primary peritoneal and fallopian tube cancerMedDRA version: 21.1Level: PTClassification code 10070907Term: Ovarian cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10070908Term: Ovarian cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-003926-18-ITISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE72
Active, not recruiting
Phase 2
A phase 2 study of pembrolizumab in combination with olaparib in patients with cervical cancer previously treated with platinum-based chemotherapyrecurrent or metastatic cervical cancercervical cancer ,Pembrolizumab,OlaparibJPRN-jRCT2031210096Hasegawa Kosei28
Active, not recruiting
Phase 1
A Phase II Study of Pembrolizumab in Subjects with Gastric CancerGastric CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-003574-16-FRMerck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.270